Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation

被引：22

作者：

Mousset, S. ^{[1
]}

Bug, G. ^{[1
]}

Heinz, W. J. ^{[2
]}

Tintelnot, K. ^{[3
]}

Rickerts, V. ^{[1
]}

机构：

[1] Klinikum JW Goethe Univ, Med Klin 2, Frankfurt, Germany

[2] Univ Klinikum Wuerzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[3] Robert Koch Inst, D-1000 Berlin, Germany

来源：

TRANSPLANT INFECTIOUS DISEASE | 2010年 / 12卷 / 03期

关键词：

zygomycosis; antifungal prophylaxis; posaconazole; breakthrough infection; stem cell transplant; graft-versus-host disease; VERSUS-HOST-DISEASE; AMPHOTERICIN-B; VORICONAZOLE; THERAPY; MUCORMYCOSIS; FLUCONAZOLE; RECIPIENTS; INFECTION; AGENT;

D O I：

10.1111/j.1399-3062.2009.00479.x

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

P>Antifungal prophylaxis with posaconazole (POS) has been shown to decrease the mortality associated with invasive fungal infections in high-risk patients. We report on a patient, with severe graft-versus-host disease after allogeneic stem cell transplantation, who developed proven pneumonia due to Rhizopus microsporus after 40 days of POS prophylaxis (fasting serum levels: 691-904 ng/mL). Despite combination treatment with liposomal amphotericin B and POS for 39 days, the patient died from pulmonary hemorrhage. This case highlights the need for continued awareness of breakthrough zygomycosis in patients receiving POS.

引用

页码：261 / 264

页数：4

共 16 条

[1] Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with Hematologic malignancy who have zygomycosis [J].

Chamilos, Georgios ;

Lewis, Russell E. ;

Kontoyiannis, Dimitrios P. .

CLINICAL INFECTIOUS DISEASES, 2008, 47 (04) :503-509

[2] Activity of posaconazole in treatment of experimental disseminated zygomycosis [J].

Dannaoui, E ;

Meis, JFGM ;

Loebenberg, D ;

Verweij, PE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) :3647-3650

[3] Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease [J].

Krishna, Gopal ;

Martinho, Monika ;

Chandrasekar, Pranatharthi ;

Ullmann, Andrew J. ;

Patino, Hernando .

PHARMACOTHERAPY, 2007, 27 (12) :1627-1636

[4] Increased Virulence of Zygomycetes Organisms Following Exposure to Voriconazole: A Study Involving Fly and Murine Models of Zygomycosis [J].

Lamaris, Gregory A. ;

Ben-Ami, Ronen ;

Lewis, Russell E. ;

Chamilos, Georgios ;

Samonis, George ;

Kontoyiannis, Dimitrios P. .

JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (09) :1399-1406

[5] Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants [J].

Marty, FM ;

Cosimi, LA ;

Baden, LR .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (09) :950-952

[6] Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro [J].

Perkhofer, Susanne ;

Locher, Maria ;

Cuenca-Estrella, Manuel ;

Ruechel, Reinhard ;

Wuerzner, Reinhard ;

Dierich, Manfred P. ;

Lass-Floerl, Cornelia .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (07) :2636-2638

[7] Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.:: Results from a global Antifungal Surveillance Program [J].

Pfaller, M. A. ;

Messer, S. A. ;

Boyken, L. ;

Tendolkar, S. ;

Hollis, R. J. ;

Diekema, D. J. .

JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (02) :551-559

[8] Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis [J].

Reed, Caitlin ;

Ibrahim, Ashraf ;

Edwards, John E., Jr. ;

Walot, Irwin ;

Spellberg, Brad .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (11) :3968-3969

[9] Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia [J].

Rickerts, V. ;

Atta, J. ;

Herrmann, S. ;

Jacobi, V. ;

Lambrecht, E. ;

Bialek, R. ;

Just-Nuebling, G. .

MYCOSES, 2006, 49 :27-30

[10] Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae [J].

Rodriguez, M. Mar ;

Serena, Carolina ;

Marine, Marcal ;

Pastor, F. Javier ;

Guarro, Josep .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (10) :3786-3788

← 1 2 →